Atlas Molecular Pharma closes a €3 million funding round led by Inveready to advance its clinical program in rare diseases

by Inveready Asset Management

The round was led by Inveready, with participation from CDTI, Grupo SPRI, Kereon Partners, Endometrial DIDI, and CRB Inverbio. This funding will enable the company to carry out a Phase I–II clinical...

Read more

SETT invests €9.9 million in digital health through the CRB Digital Health III fund

by CRB Health Tech

Through this public investment, CRB Digital Health III will provide resources to digital health start-ups and scale-ups, particularly those with disruptive intellectual property in growth stages and w...

Read more

CRB Inverbío has led the €4M Series A round of Zoundream

by CRB Health Tech

Zoundream is pioneering the use of AI in pediatric health by transforming infant cries into real-time clinical insights. Babies cry for an average of 2–3 hours a day, yet caregivers are often left g...

Read more

CRB Inverbío participates in Prosoma’s Series A funding round

by CRB Health Tech

CRB Inverbío is thrilled to welcome Prosoma as the newest addition to its portfolio. The firm has recently participated in Prosoma’s Series A funding round, joining Verge and Impact Ventures to sup...

Read more

CRB Inverbío amplía su portafolio con un tercer fondo dedicado a proyectos de Salud Digital con un tamaño de hasta €40 millones

by CRB Health Tech

CRB Inverbío amplía su portafolio con un tercer fondo de capital riesgo dedicado a proyectos de Salud Digital tanto españoles como europeos de tamaño de hasta 40 millones de euros, y expande con e...

Read more

CRB Inverbío y Progenika refuerzan Mecwins con 4 millones de euros

by CRB Health Tech

​La sociedad de capital riesgo CRB Inverbío y Progenika Biopharma, una compañía del grupo Grifols, han redoblado su apuesta por la compañía Mecwins mediante una aportación de 2 millones de eu...

Read more

CIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases

by CRB Health Tech

The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chape...

Read more

El fondo de capital riesgo CRB Bio II compromete 2 millones de Euros en Aglaris Ltd

by CRB Health Tech

Gracias a esta financiación, la compañía comenzará en los próximos meses la materialización de su biorreactor, una tecnología de cultivo automatizado de células madre que permite importantes a...

Read more

Novedad en los fondos biotecnológicos en España

by Abra Invest

En España se están consolidando un número reducido de inversores de capital riesgo especializados en biotecnología. Algunos de ellos están recibiendo el apoyo de inversores internacionales y otro...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Xcalibur Smart Mapping strengthens its g...

by MCH Private Equity

​Xcalibur Smart Mapping, recognised as the global leader in airborne...

Photos Stream